Search clinical trials for: BG9588

Total 16 results

National Institute of Diabetes and Digestive and...

Completed

Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation

Kidney Transplantation

United States
National Institute of Arthritis and Musculoskeletal...

Completed

BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis

Lupus Nephritis | Glomerulonephritis, Membranoproliferative

United States
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Biotest

Completed

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 (ESsCOVID)

Covid19

Brazil, France, Russian Federation, Spain
Biotest

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) (ESsCAPE)

Community-acquired Pneumonia

Australia, Spain, Israel, France, Brazil, Germany, United States, Philippines, Belgium, Romania, Czechia, Hungary, Austria, Argentina, South Africa
Biotest

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia (TRICOVID)

COVID-19 | Pneumonia | Acute Respiratory Distress Syndrome | Community-acquired Pneumonia | Respiratory Infection | Bacterial Pneumonia | Viral Pneumonia | Fungal Pneumonia

Belgium, Brazil, Latvia, Germany, Lithuania, South Africa, Argentina, Austria, France, Hungary, Slovakia, Turkey, Portugal, Spain
Biogen

Completed

Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study (AVAIL)

Multiple Sclerosis

Belgium
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
Biogen

Completed

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Multiple Sclerosis | Pregnancy | Prenatal Exposure Delayed Effects

United States
Biogen

Terminated

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

Multiple Sclerosis

United States
Biogen

Completed

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

Active Ulcerative Colitis

United States, Canada, Czech Republic, Hungary, Poland, Russian Federation, Slovakia
Biogen

Completed

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency (TRIDENT-1)

Renal Insufficiency | Congestive Heart Failure

Israel, Italy, United States, Finland, Canada, Australia, France, Netherlands, Poland, Bulgaria, Russian Federation, India, Brazil, Sweden, Romania, Czechia, Argentina, Germany
Biogen

Completed

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

Multiple Sclerosis

United States
Biogen

Recruiting

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis

United States, Germany
Biogen

Terminated

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency (POSEIDON)

Heart Failure | Renal Insufficiency

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States

Search clinical trials for: BG9588

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations